{"id":36946,"date":"2025-10-25T15:57:33","date_gmt":"2025-10-25T08:57:33","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=36946"},"modified":"2025-10-25T15:57:33","modified_gmt":"2025-10-25T08:57:33","slug":"cardiovalve-completes-target-study-enrollment-for-ce-registration-study-for-tricuspid-valve-replacement","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=36946","title":{"rendered":"Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement"},"content":{"rendered":"<p><b><span>The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch<\/span><\/b><\/p>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">HANGZHOU, China<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Oct. 25, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0Venus\u00a0Medtech (<span class=\"xn-location\">Hangzhou<\/span>) Inc. (2500.HK, hereinafter referred to as the &#8220;Company&#8221;) today announced the successful completion of patient enrollment in the <b>Cardiovalve TARGET study<\/b> for Transcatheter Tricuspid Valve Replacement (TTVR), with a total of <b>150 patients enrolled<\/b>. The completion of enrollment marks a major milestone toward European regulatory approval for Cardiovalve&#8217;s <b>Transcatheter Tricuspid Valve Replacement (TTVR) system<\/b>, the company&#8217;s flagship solution for treating tricuspid regurgitation.<\/p>\n<p>With enrollment now complete, the company is preparing to submit its <b>CE Mark application<\/b> to European regulators later this year. Pending approval, <b>commercial launch of the Cardiovalve TR system in <span class=\"xn-location\">Europe<\/span> is projected for 2027<\/b>.<\/p>\n<p>Building on this achievement, Cardiovalve is also preparing to initiate its <b>AHEAD study<\/b>, which will evaluate the safety and performance of Cardiovalve&#8217;s <b>mitral valve replacement system<\/b> in patients suffering from significant mitral regurgitation (MR). The AHEAD study is designed to support a future <b>CE Mark application<\/b> for the mitral system.<\/p>\n<p><b>Cardiovalve Participation at TCT 2025<\/b><\/p>\n<p>Cardiovalve will present preliminary data for its mitral regurgitation (MR) system at <b>TCT 2025<\/b>.<\/p>\n<p>The presentation, titled &#8220;Transcatheter Mitral Valve Replacement Using the New Generation Cardiovalve System,&#8221; will be led by <b>Dr. <span class=\"xn-person\">Christian Frerker<\/span>.<\/b><\/p>\n<p><b>Session Details<\/b>:<\/p>\n<ul type=\"disc\">\n<li><b>Session<\/b>: Innovation Session 17 \u2014 New Generation Transcatheter Mitral Technologies: Case-in-a-Box Demonstrations<\/li>\n<li><b>Date<\/b>: <span class=\"xn-chron\">Tuesday, October 28, 2025<\/span><\/li>\n<li><b>Time<\/b>: 12:25\u201312:30 PM<\/li>\n<li><b>Location<\/b>: Moscone Center, North, Exhibition Level, Hall E- Innovation Theatre<\/li>\n<\/ul>\n<p><b>About Cardiovalve<\/b><\/p>\n<p>A subsidiary of <b>Venus Medtech<\/b>, <b>Cardiovalve<\/b> is a pioneer in transcatheter valve replacement technology, standing at the forefront of innovation in structural heart therapy. With more than <b>150 approved patents<\/b>, a highly experienced team, and a <b>state-of-the-art manufacturing facility<\/b>, Cardiovalve is dedicated to providing physicians with next-generation solutions that improve patient outcomes and quality of life\u2014without the need for open-heart surgery.<\/p>\n<p><b>About Venus Medtech<\/b><\/p>\n<p><b>Venus Medtech (<span class=\"xn-location\">Hangzhou<\/span>) Inc. (2500.HK)<\/b> is a leading innovator in transcatheter heart valve solutions for structural heart disease. The company has developed a comprehensive product pipeline covering all four heart valves \u2014 <b>TAVR, TPVR, TMVR, and TTVR<\/b> \u2014and related accessory products. With global R&amp;D centers in <span class=\"xn-location\">China<\/span>, <span class=\"xn-location\">the United States<\/span>, and <span class=\"xn-location\">Israel<\/span>, The company is committed to providing effective treatment solutions for life-threatening diseases.<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p><b><span>The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch<\/span><\/b><\/p>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">HANGZHOU, China<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Oct. 25, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0Venus\u00a0Medtech (<span class=\"xn-location\">Hangzhou<\/span>) Inc. (2500.HK, hereinafter referred to as the &#8220;Company&#8221;) today announced the successful completion of patient enrollment in the <b>Cardiovalve TARGET study<\/b> for Transcatheter Tricuspid Valve Replacement (TTVR), with a total of <b>150 patients enrolled<\/b>. The completion of enrollment marks a major milestone toward European regulatory approval for Cardiovalve&#8217;s <b>Transcatheter Tricuspid Valve Replacement (TTVR) system<\/b>, the company&#8217;s flagship solution for treating tricuspid regurgitation.<\/p>\n<p>With enrollment now complete, the company is preparing to submit its <b>CE Mark application<\/b> to European regulators later this year. Pending approval, <b>commercial launch of the Cardiovalve TR system in <span class=\"xn-location\">Europe<\/span> is projected for 2027<\/b>.<\/p>\n<p>Building on this achievement, Cardiovalve is also preparing to initiate its <b>AHEAD study<\/b>, which will evaluate the safety and performance of Cardiovalve&#8217;s <b>mitral valve replacement system<\/b> in patients suffering from significant mitral regurgitation (MR). The AHEAD study is designed to support a future <b>CE Mark application<\/b> for the mitral system.<\/p>\n<p><b>Cardiovalve Participation at TCT 2025<\/b><\/p>\n<p>Cardiovalve will present preliminary data for its mitral regurgitation (MR) system at <b>TCT 2025<\/b>.<\/p>\n<p>The presentation, titled &#8220;Transcatheter Mitral Valve Replacement Using the New Generation Cardiovalve System,&#8221; will be led by <b>Dr. <span class=\"xn-person\">Christian Frerker<\/span>.<\/b><\/p>\n<p><b>Session Details<\/b>:<\/p>\n<ul type=\"disc\">\n<li><b>Session<\/b>: Innovation Session 17 \u2014 New Generation Transcatheter Mitral Technologies: Case-in-a-Box Demonstrations<\/li>\n<li><b>Date<\/b>: <span class=\"xn-chron\">Tuesday, October 28, 2025<\/span><\/li>\n<li><b>Time<\/b>: 12:25\u201312:30 PM<\/li>\n<li><b>Location<\/b>: Moscone Center, North, Exhibition Level, Hall E- Innovation Theatre<\/li>\n<\/ul>\n<p><b>About Cardiovalve<\/b><\/p>\n<p>A subsidiary of <b>Venus Medtech<\/b>, <b>Cardiovalve<\/b> is a pioneer in transcatheter valve replacement technology, standing at the forefront of innovation in structural heart therapy. With more than <b>150 approved patents<\/b>, a highly experienced team, and a <b>state-of-the-art manufacturing facility<\/b>, Cardiovalve is dedicated to providing physicians with next-generation solutions that improve patient outcomes and quality of life\u2014without the need for open-heart surgery.<\/p>\n<p><b>About Venus Medtech<\/b><\/p>\n<p><b>Venus Medtech (<span class=\"xn-location\">Hangzhou<\/span>) Inc. (2500.HK)<\/b> is a leading innovator in transcatheter heart valve solutions for structural heart disease. The company has developed a comprehensive product pipeline covering all four heart valves \u2014 <b>TAVR, TPVR, TMVR, and TTVR<\/b> \u2014and related accessory products. With global R&amp;D centers in <span class=\"xn-location\">China<\/span>, <span class=\"xn-location\">the United States<\/span>, and <span class=\"xn-location\">Israel<\/span>, The company is committed to providing effective treatment solutions for life-threatening diseases.<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-36946","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/36946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36946"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/36946\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36946"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36946"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}